Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900644 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTGAAHSP90AA1HSD17B10 | |
| SCHEMBL7561838 | 0.83 | MAPT (0.49) | ALDH1A1MAPTGAAHSD17B10POLB | |
| SCHEMBL26616888 | 0.83 | MAPT (0.49) | ALDH1A1MAPTGAAHSD17B10POLB | |
| SCHEMBL27541360 | 0.81 | PPARG (0.37) | ALDH1A1MAPTGAAPOLBHPGD | |
| SCHEMBL4527204 | 0.79 | KEAP1 (0.50) | ALDH1A1MAPTGAAHSP90AA1HPGD | |
| SCHEMBL8530526 | 0.79 | MAPK1 (0.39) | ALDH1A1MAPTGAAHSD17B10HPGD | |
| SCHEMBL27744373 | 0.79 | KEAP1 (0.50) | ALDH1A1MAPTGAAHSP90AA1HPGD | |
| SCHEMBL4522437 | 0.79 | KEAP1 (0.50) | ALDH1A1MAPTGAAHSP90AA1HPGD | |
| SCHEMBL8526965 | 0.78 | ITGB1 (0.41) | ALDH1A1MAPTGAAHSD17B10HPGD | |
| SCHEMBL4526295 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAPTGAAHSD17B10NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231532-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20180099923-A1 | Supported Metal Catalysts | JOHNSON MATTHEY PLC (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-2536500-B1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2016-12-07 | — | — | EP | disclosed |
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-2536500-A1 | SUPPORTED METAL CATALYSTS | Johnson Matthey PLC (GB) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101679-A1 | SUPPORTED METAL CATALYSTS | JOHNSON MATTHEY PLC (GB) | 2011-08-25 | — | — | WO | disclosed |
| EP-1250353-B1 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | CYCLACEL LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-7449544-B2 | p21 peptides | CYCLACEL LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-20060293245-A1 | P21 derived peptides and uses thereof | CYCLACEL LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-20050153894-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20040176301-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| US-20030036628-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2003-02-20 | — | — | US | disclosed |
| EP-1250353-A2 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | Cyclacel Limited (GB) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001040142-A2 | P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES | CYCLACEL LIMITED (GB) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072722-A1 | SUPPORTED METAL CATALYSTS | SOD1, HNMT, SOD3 | ALDH1A1 1906/4885MAPT 2539/4885GAA 1669/4885 |
| US-20060293245-A1 | P21 derived peptides and uses thereof | CDK4, CDK2AP2, CDK2 | ALDH1A1 3629/4885MAPT 4602/4885GAA 3067/4885 |
| US-20050153894-A1 | p21 peptides | CDK2, CDK4, CDKN1A | ALDH1A1 3942/4885MAPT 4551/4885GAA 2982/4885 |
| US-20040176301-A1 | p21 peptides | CDK2, CDK4, CDKN1A | ALDH1A1 3942/4885MAPT 4551/4885GAA 2982/4885 |
| US-20030036628-A1 | p21 peptides | CDK2, CDK4, CDKN1A | ALDH1A1 3942/4885MAPT 4551/4885GAA 2982/4885 |
| US-20200231532-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | ALDH1A1 1906/4885MAPT 2539/4885GAA 1669/4885 |
| US-20180099923-A1 | Supported Metal Catalysts | SOD1, HNMT, SOD3 | ALDH1A1 1906/4885MAPT 2539/4885GAA 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.